Clinical Trial News and Research

RSS

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Raptor Pharmaceutical Corp., announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population.

12 Oct 2009

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.

12 Oct 2009

FDA approves Berinert for the treatment of hereditary angioedema

The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).

12 Oct 2009

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

Eric Boerwinkle, Ph.D., a professor at The University of Texas Health Science Center at Houston, has received a $26 million federal stimulus grant to lead an effort to pinpoint genetic factors affecting the risk of heart, lung and blood diseases.

12 Oct 2009

Phase I clinical trial results for Fentanyl Lauriad announced by BioAlliance Pharma

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency (AFSSaPS) to enter first Phase I clinical trial for Fentanyl Lauriad®.

12 Oct 2009

Presentations on efficacy of interferon to combat influenza

Amarillo Biosciences, Inc. (ABI) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza.

12 Oct 2009

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

The National Institutes of Health is preparing to launch the first government-sponsored clinical trial to determine what dose of the 2009 H1N1 influenza vaccine is needed to induce a protective immune response in people with asthma, especially those with severe disease.

12 Oct 2009

Clinical trial reveals cholera vaccine is safe, offers protection for up to 2 years

A clinical trial of an Indian-made "modified killed-whole-cell" oral cholera vaccine "that meets WHO standards" has found that the vaccine is safe and effective in children living in parts of India where the disease is endemic, Reuters reports. The researchers, who reported their findings in the journal Lancet, hope to soon introduce the vaccine into other cholera endemic settings.

9 Oct 2009

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

9 Oct 2009

Riley Hospital for Children commences patient enrollment in clinical trial of cystic fibrosis drug

The Riley Hospital for Children Cystic Fibrosis Center is the first site in the nation to enroll patients ages 6-11 for the first part of a 48-week clinical trial of a promising investigational treatment for cystic fibrosis (CF).

9 Oct 2009

OncoGenex Pharmaceuticals president named Canada's Pacific Ernst & Young's Entrepreneur Of The Year

OncoGenex Pharmaceuticals, Inc., announced today that Scott Cormack, president and chief executive officer of OncoGenex, has been named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R). The Ernst & Young Entrepreneur Of The Year(R) Award is a high profile business award recognizing entrepreneurs that are building successful, dynamic businesses.

9 Oct 2009

New soy germ-based ingredient improves menopausal symptoms

SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women.

9 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

Refurbished pacemakers: No complications for patients

Patients who received refurbished pacemakers donated from Detroit area funeral homes survived without complications from the devices, according to a case series reported by the University of Michigan Cardiovascular Center.

9 Oct 2009

Chinese health experts look to control spread of H1N1 In country's remote regions

As epidemiologists in China continue to investigate the country's first death from H1N1 (swine flu), Chinese health experts have called for strengthened measures to control the spread of the virus in remote regions, China Daily reports.

9 Oct 2009

Lpath reports positive Phase 1 clinical trial results of iSONEP in wet-AMD patients

Lpath, Inc., the category leader in lipidomics-based therapeutics, reported positive summary results of its single-dose Phase 1 clinical trial of iSONEP™ in wet-AMD patients.

8 Oct 2009

Valensa initiates licensing patent for the use of the astaxanthin as a dietary supplement

Valensa International (Orlando, FL USA) announced today that it has initiated a broad out licensing effort for University of Illinois patent (US 5,527,533 and its foreign equivalents) for the use of the astaxanthin in eye healthcare dietary supplement applications.

8 Oct 2009

Macuclear and Mystic announce groundbreaking results from Phase Ib Clinical Trial for Macular Degeneration

MacuCLEAR, Inc. and Mystic Pharmaceuticals, Inc., announced today preliminary successful results of a Phase Ib Clinical Trial for the treatment and prevention of the progression of Age Related Macular Degeneration (AMD). The preliminary results indicated that MacuCLEAR’s MC-1101 drug is safe and well tolerated by study participants, and has a biological effect on blood flow in the back of the retina.

8 Oct 2009

Mitraclip is an experimental and controversial procedure, says heart specialist

Seventy-seven year-old Hollywood legend Elizabeth Taylor announced on Tuesday she was having a Mitraclip heart procedure. Leading cardiothoracic surgeon and heart surgery expert Dr. Lishan Aklog, M.D. appeared on EmpowHer, the home of women's health online, to explain why her surgery is "experimental and controversial."

8 Oct 2009

Reverse Medical Corporation commences human use of its ReStore Microcatheter

Reverse Medical Corporation announced today they have initiated human use of their ReStore™ Microcatheter for reestablishing blood flow in the Neurovasculature. The device was successfully used in an acute ischemic stroke patient in Germany.

8 Oct 2009

Clinical Trial News and Research

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

FDA approves Berinert for the treatment of hereditary angioedema

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

Phase I clinical trial results for Fentanyl Lauriad announced by BioAlliance Pharma

Presentations on efficacy of interferon to combat influenza

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

Clinical trial reveals cholera vaccine is safe, offers protection for up to 2 years

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

Riley Hospital for Children commences patient enrollment in clinical trial of cystic fibrosis drug

OncoGenex Pharmaceuticals president named Canada's Pacific Ernst & Young's Entrepreneur Of The Year

New soy germ-based ingredient improves menopausal symptoms

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Refurbished pacemakers: No complications for patients

Chinese health experts look to control spread of H1N1 In country's remote regions

Lpath reports positive Phase 1 clinical trial results of iSONEP in wet-AMD patients

Valensa initiates licensing patent for the use of the astaxanthin as a dietary supplement

Macuclear and Mystic announce groundbreaking results from Phase Ib Clinical Trial for Macular Degeneration

Mitraclip is an experimental and controversial procedure, says heart specialist

Reverse Medical Corporation commences human use of its ReStore Microcatheter

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer